ClinicalTrials.gg
Status unknownNCT01893840Updated Oct 31, 2013

Effect on Blood Flow Using the FlowOx™ Device in Patients With Reduced Peripheral Circulation in the Lower Leg

An interventional study of FlowOx in Periferal Arterial Occlusive Disease, PAOD, sponsored by Otivio AS. Status unknown at 1 site in Norway. Open to participants aged 30 Years to 90 Years. Per ClinicalTrials.gov, last updated 2013-10-31.

Sponsored by Otivio AS · Not applicable and Interventional

How we know

The sponsor has not verified this record recently (last verified Oct 2013), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
30 Years to 90 Years
Sex
All
01

Study summary

A study to assess the effect of negative pulsating pressure therapy on patients with impaired blood flow to the leg caused by arterial disease, to see if the FlowOx device will increase the blood flow to the leg in these patients.

02

Conditions studied

  • Periferal Arterial Occlusive Disease, PAOD
03

In context

Arterial Occlusive Diseases

230 studies on the registry are indexed under Arterial Occlusive Diseases; 27 are open to participants now.

This study's planned enrollment of 20 is below the median of 184 across 157 interventional studies indexed under Arterial Occlusive Diseases.

Browse Arterial Occlusive Diseases studies →

Lead sponsor

Otivio AS is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Age 30-90 years
  • Affected foot/shoe sise less than 46 (approximate foot length less than 29.5 cm)
  • Patients with Peripheral Arterial Occlusive Disease (PAOD) grade 2,3 or 4, i.e.:

    1. Clinically verified grade 2, i.e. Intermittent Claudication:

      • Ancle-Brachial Index (ABI)less than 0.9 or
      • Toe brachial Index (TBI) less than 0.7 or
      • Ultrasound and/or CT/Magnetic Resonance (MR) angiography suggesting stenosis(es)and/or occlusion(s)
    2. Clinically verified grade 3, i.e. Critical Limb Ischemia (CLI):

      • ABI less than 0.4 or
      • Toe pressure less than 30 mmHg
      • Rest pain since at least 2 weeks or
      • Use of analgesics for rest pain for at least 2 weeks or
      • Ultrasound and/or CT/Magnetic Resonance (MR) angiography suggesting stenosis(es)and/or occlusion(s)
    3. Clinically verified grade 4, i.e. CLI:

      • Ischemic ulcers or gangrene/tissue loss
      • ABI less than 0.4
      • Toe pressure less than 30 mmHg
      • Rest pain since at least 2 weeks or
      • Use of analgesics for rest pain for at least 2 weeks or
      • Ultrasound and/or CT/MR angiography suggesting stenosis(es)and/or occlusion(s)

Exclusion criteria

Exclusion Criteria:

  • Grade 1 PAOD
  • Incapable of consenting voluntarily
  • Fewer higher than 39 degrees Centigrade
  • Severe (COPD)
  • Severe heart disease such as unstable angina, severe heart failure and severe valve failure
  • Severe Polyneurophathy
  • Verified Osteomyelitis other than in the Phanlanx
  • Currently treated for cancer and With a of less than 2 years
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    FlowOx

    5 minutes of pulsating negative pressure (10 sek og -40mmHg/7 sek of athmospheric pressure) will be Applied to the patient's leg

    Device: FlowOx

Interventions

  • DeviceFlowOx

    Boot-shaped pressure chamber generating pulsating negative pressure

06

What researchers measure

Primary outcomes

  1. % of the prescribed cycles delivered in the specified time FlowOx™-induced change in arterial leg blood flow (LBF)

    This is calculated as the difference between the blood flow during the period using FlowOx™ (middle value over a period of 5 minutes) and baseline blood flow (middle value over a period of 5 prior to using FlowOx™)

    Time frame: up to 1 hour

Secondary outcomes

  1. Patient comfort measured by asking the patient a fixed set of questions

    Time frame: up to 1 hour

Other outcomes

  1. Fitting time

    Time frame: up to 1 hour

07

Study locations

1 site
  • Akershus University Hospital
    Lørenskog, N-1478, Norway
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2013
First posted
Jul 9, 2013
Start
Aug 2013
Primary completionEst.
Dec 2013
CompletionEst.
Dec 2013
Last update
Oct 31, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01893840
Lead sponsor
Otivio AS
Collaborators
European Union, The Research Council of Norway
Responsible party
Sponsor
First posted
Jul 9, 2013
Start date
Aug 2013
Primary completion
Dec 2013 (estimated)
Completion
Dec 2013 (estimated)
Last update
Oct 31, 2013

Study contacts

Jarlis Wesche, PhD
principal investigator · Principal Investigator

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion